Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W M Ridgway

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Clinical Immunology and Immunopathology|January 22, 1998
The association of MHC with autoimmune diseases: understanding the pathogenesis of autoimmune diabetesW M Ridgway, C G Fathman
Current Opinion in Immunology|January 13, 2000
MHC structure and autoimmune T cell repertoire developmentW M Ridgway, C G Fathman
Hospital Practice (Office Ed.)|September 15, 1993
Aggressive drug therapy for rheumatoid arthritisJ L McGuire, W M Ridgway
Journal of Immunology (Baltimore, Md. : 1950)|July 24, 2001
Increased entry into the IFN-gamma effector pathway by CD4+ T cells selected by I-Ag7 on a nonobese diabetic versus C57BL/6 genetic backgroundS Koarada, Y Wu, W M Ridgway
Current Opinion in Immunology|December 1, 1994
Regulation of autoimmune responseW M Ridgway, H L Weiner, C G Fathman
The Journal of Experimental Medicine|April 1, 1996
Breaking self-tolerance in nonobese diabetic miceW M Ridgway, M Fassò, A Lanctot, et al.
The Journal of Experimental Medicine|December 22, 1998
Analysis of the role of variation of major histocompatibility complex class II expression on nonobese diabetic (NOD) peripheral T cell responseW M Ridgway, H Ito, M Fassò, et al.
Transplantation|March 9, 2000
Identification and characterization of the antigen-specific subpopulation of alloreactive CD4+ T cells in vitro and in vivoN R Krieger, C G Fathman, M K Shaw, et al.
The Journal of Experimental Medicine|December 20, 2000
T cell receptor (TCR)-mediated repertoire selection and loss of TCR vbeta diversity during the initiation of a CD4(+) T cell response in vivoM Fassò, N Anandasabapathy, F Crawford, et al.
Clinical and Experimental Immunology|May 6, 2016
Endogenous interleukin-22 protects against inflammatory bowel disease but not autoimmune cholangitis in dominant negative form of transforming growth factor beta receptor type II miceG-X Yang, Y Sun, K Tsuneyama, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Clinical Immunology and Immunopathology|January 22, 1998
The association of MHC with autoimmune diseases: understanding the pathogenesis of autoimmune diabetesW M Ridgway, C G Fathman
Current Opinion in Immunology|January 13, 2000
MHC structure and autoimmune T cell repertoire developmentW M Ridgway, C G Fathman
Hospital Practice (Office Ed.)|September 15, 1993
Aggressive drug therapy for rheumatoid arthritisJ L McGuire, W M Ridgway
Journal of Immunology (Baltimore, Md. : 1950)|July 24, 2001
Increased entry into the IFN-gamma effector pathway by CD4+ T cells selected by I-Ag7 on a nonobese diabetic versus C57BL/6 genetic backgroundS Koarada, Y Wu, W M Ridgway
Current Opinion in Immunology|December 1, 1994
Regulation of autoimmune responseW M Ridgway, H L Weiner, C G Fathman
The Journal of Experimental Medicine|April 1, 1996
Breaking self-tolerance in nonobese diabetic miceW M Ridgway, M Fassò, A Lanctot, et al.
The Journal of Experimental Medicine|December 22, 1998
Analysis of the role of variation of major histocompatibility complex class II expression on nonobese diabetic (NOD) peripheral T cell responseW M Ridgway, H Ito, M Fassò, et al.
Transplantation|March 9, 2000
Identification and characterization of the antigen-specific subpopulation of alloreactive CD4+ T cells in vitro and in vivoN R Krieger, C G Fathman, M K Shaw, et al.
The Journal of Experimental Medicine|December 20, 2000
T cell receptor (TCR)-mediated repertoire selection and loss of TCR vbeta diversity during the initiation of a CD4(+) T cell response in vivoM Fassò, N Anandasabapathy, F Crawford, et al.
Clinical and Experimental Immunology|May 6, 2016
Endogenous interleukin-22 protects against inflammatory bowel disease but not autoimmune cholangitis in dominant negative form of transforming growth factor beta receptor type II miceG-X Yang, Y Sun, K Tsuneyama, et al.
Pageof 2